These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6089559)

  • 1. Angiotensin II-mediated vasoconstriction in chronic congestive heart failure, and response to converting enzyme inhibition.
    Cody RJ
    Am J Med; 1984 Aug; 77(2A):71-7. PubMed ID: 6089559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conceptual and therapeutic approaches to inhibition of the renin-angiotensin system in chronic heart failure.
    Cody RJ
    J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S58-65. PubMed ID: 2422494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril.
    Turini GA; Waeber B; Brunner HR
    Eur Heart J; 1983 Jan; 4 Suppl A():189-97. PubMed ID: 6301835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.
    Cody RJ
    Drugs; 1984 Aug; 28(2):144-69. PubMed ID: 6205842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate converting-enzyme inhibition with intravenous enalapril in chronic congestive heart failure.
    Kubo SH; Cody RJ; Laragh JH; Prida XE; Atlas SA; Yuan Z; Sealey JE
    Am J Cardiol; 1985 Jan; 55(1):122-6. PubMed ID: 2981462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Converting enzyme inhibition to identify and treat renin-mediated or sodium-volume related forms of increased peripheral resistance in hypertension and in congestive heart failure.
    Cody RJ; Laragh JH; Atlas SA; Case DB
    J Hypertens Suppl; 1983 Oct; 1(1):77-84. PubMed ID: 6085835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril.
    Atlas SA; Case DB; Yu ZY; Laragh JH
    Am J Med; 1984 Aug; 77(2A):13-7. PubMed ID: 6089554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic effects of angiotensin and renin inhibition in dogs with acute left ventricular failure.
    Sweet CS; Ludden CT; Frederick CM; Ribeiro LG
    Am J Med; 1984 Aug; 77(2A):7-12. PubMed ID: 6089558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enalapril (MK-421), a new angiotensin-converting enzyme inhibitor. Acute and chronic effects in heart failure.
    Dunkman WB; Wilen M; Franciosa JA
    Chest; 1983 Nov; 84(5):539-45. PubMed ID: 6313304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redistribution of regional blood flow following angiotensin-converting enzyme inhibition. Comparison of normal subjects and patients with heart failure.
    Faxon DP; Creager MA; Halperin JL; Bernard DB; Ryan TJ
    Am J Med; 1984 May; 76(5B):104-10. PubMed ID: 6203405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic.
    Packer M
    Int J Cardiol; 1985 Feb; 7(2):111-20. PubMed ID: 2982750
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and hemodynamic experience with enalapril in congestive heart failure.
    Cody RJ
    Am J Cardiol; 1985 Jan; 55(2):36A-40A. PubMed ID: 2981464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of the clinical pharmacology of enalapril.
    Davies RO; Gomez HJ; Irvin JD; Walker JF
    Br J Clin Pharmacol; 1984; 18 Suppl 2(Suppl 2):215S-229S. PubMed ID: 6099737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme inhibitors in congestive heart failure. Overview in comparison of captopril and enalapril.
    Levine TB; Olivari MT; Cohn JN
    Am J Med; 1986 Oct; 81(4C):36-9. PubMed ID: 3022583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurohormonal activation and the response to converting enzyme inhibitors in congestive heart failure.
    Kubo SH
    Circulation; 1990 Feb; 81(2 Suppl):III107-14. PubMed ID: 2137052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unrelated responses of brachial artery hemodynamics and renin-angiotensin system to acute converting enzyme inhibition by enalaprilat in essential hypertension.
    Levenson J; Chau NP; Billaud E; Simon A
    Am J Cardiol; 1988 May; 61(13):1056-60. PubMed ID: 2834938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Galvao M
    Heart Lung; 1990 Sep; 19(5 Pt 1):505-11. PubMed ID: 2211159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure.
    De Marco T; Daly PA; Liu M; Kayser S; Parmley WW; Chatterjee K
    J Am Coll Cardiol; 1987 May; 9(5):1131-8. PubMed ID: 3033043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation.
    Su J; Barbe F; Houël R; Guyene TT; Crozatier B; Hittinger L
    Basic Res Cardiol; 1999 Apr; 94(2):128-35. PubMed ID: 10326661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.